Abstract
Epstein-Barr virus (EBV) is a ubiquitous infection. In the setting of hematopoietic cell transplantation (HCT), EBV-associated post-transplantation lymphoproliferative disorder (EBV-PTLD) is a recognized complication. Particular approaches to graft manipulation and the prevention or treatment of graft-versus-host disease are associated with increased risk of EBV-PTLD. Other donor and host factors may also contribute to risk. In some series, the risk of EBV-PTLD has exceeded 25%, whereas in others the risk is 1% or less. In this chapter, aspects of EBV biology relevant to HCT patients are reviewed with a focus on EBV-PTLD risk factors, prevention, clinical manifestations, and treatment. The utility of EBV monitoring in the post-HCT period and evolving approaches to the treatment of EBV-associated malignancies are discussed.
| Original language | English (US) |
|---|---|
| Title of host publication | Thomas' Hematopoietic Cell Transplantation |
| Subtitle of host publication | Fifth Edition |
| Publisher | Wiley-Blackwell |
| Pages | 1105-1113 |
| Number of pages | 9 |
| Volume | 2-2 |
| ISBN (Electronic) | 9781118416426 |
| ISBN (Print) | 9781118416006 |
| DOIs | |
| State | Published - Jan 1 2016 |
Keywords
- Allogeneic hematopoietic cell transplantation
- Epstein-Barr virus
- Epstein-Barr virus DNA
- Epstein-Barr virus-specific cytotoxic T-lymphocytes
- Graft manipulation
- Immunosuppression
- Latent infection
- Post-transplantation lymphoproliferative disorder
- Rituximab
- T-cell depletion
ASJC Scopus subject areas
- Medicine(all)